Novo Nordisk (NVO) Partners With OpenAI to Speed Drug Discovery

TLDR

• Novo Nordisk announced a partnership with OpenAI to use AI across drug discovery, manufacturing, and commercial operations.
• NVO stock rose 2.8% shortly after the opening bell following the announcement.
• The deal will use OpenAI’s technology to analyze complex datasets and identify promising drug candidates.
• CEO Mike Doustdar said the goal is to “supercharge” scientists, not replace them, though future hiring will be slowed.
• Pilot programs will begin across R&D, manufacturing, and commercial operations, with full integration planned by end of 2026.

Novo Nordisk ($NVO) has struck a partnership with OpenAI to deploy artificial intelligence across its business, from drug discovery to manufacturing and supply chain. The news sent the stock up 2.8% shortly after Tuesday’s opening bell.

Novo Nordisk A/S, NVO

The Danish drugmaker said the deal will allow it to analyze complex datasets, identify promising drug candidates, and cut down the time it takes to move a medicine from the research stage to patients. Financial terms were not disclosed.

CEO Mike Doustdar was direct about the intent. “The aim here is not replacing our scientists. It’s about supercharging them,” he said. OpenAI CEO Sam Altman added that AI can help “people live better, longer lives” in life sciences.

The partnership comes as Novo finds itself in an intense battle for dominance in the weight-loss drug market. Eli Lilly won U.S. approval for its weight-loss pill Foundayo earlier this month, while Novo launched oral Wegovy in January. Analysts forecast annual revenue from weight-loss drugs to exceed $100 billion in the next decade.

What the Deal Actually Covers

Pilot programs will begin across R&D, manufacturing, and commercial operations, with full integration targeted by the end of 2026. OpenAI will also train Novo’s global workforce to lift AI literacy and productivity across departments.

Novo said the partnership includes strict data protection, governance, and human oversight provisions. It builds on existing AI work, including a collaboration with Nvidia to use the Gefion sovereign AI supercomputer for drug discovery.

Doustdar said AI would help employees work faster and more effectively, reducing the need to grow headcount at the pace it has in the past. Shortly after taking over as CEO last year, he announced a restructuring that cut 9,000 jobs.

AI in Drug Development: Still Early Days

While the OpenAI deal signals ambition, industry experts are clear-eyed about where AI currently delivers value. The technology has made progress in areas like identifying clinical trial participants and selecting sites, but has not yet fully cracked the harder problem of discovering major new molecules.

Drugmakers across the industry are leaning into AI to streamline the more tedious parts of drug development, from preparing regulatory filings to running supply chains. Novo is positioning itself at the front of that effort.

As of Tuesday, NVO was trading up 1.42% in after-hours.

The post Novo Nordisk (NVO) Partners With OpenAI to Speed Drug Discovery appeared first on CoinCentral.